| (Values in U.S. Thousands) | Dec, 2016 | Dec, 2015 | Dec, 2014 | Dec, 2013 | Dec, 2012 |
| Sales | 9,230 | 8,270 | 1,320 | 400 | 200 |
| Sales Growth | +11.61% | +526.51% | +230.00% | +100.00% | +100.00% |
| Net Income | -16,230 | -17,350 | -14,520 | 12,890 | -10,450 |
| Net Income Growth | +6.46% | -19.49% | -212.65% | +223.35% | -18.35% |
Rosetta Genomics Ltd (ROSG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Rosetta Genomics, Ltd. was incorporated under the laws of the State of Israel on March 9, 2000 as Rosetta Genomics Ltd., an Israeli company. It is a development stage company that seeks to develop and commercialize new diagnostic tests based on a recently discovered group of genes known as microRNAs. MicroRNAs are naturally expressed, or produced, using instructions encoded in DNA. It has established a CLIA-certified laboratory in Philadelphia, which enables it to develop, validate and commercialize its own diagnostic tests applying its microRNA technology. In addition, it is developing body fluid-based diagnostic tests, for other potential indication as part of its longer-term pipeline. The Company is currently focusing on the development and commercialization of new diagnostic tests based on microRNAs. Its industry is highly competitive and subject to rapid and significant technological change.